Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases

Viamet Pharmaceuticals, Inc. today announced that Chief Development Officer, Amir Tavakkol, Ph.D., Dip. Bacteriol, will present data from the Company’s VT-1161 therapeutic program in the treatment of onychomycosis, or fungal nail infection, at the 4th International Summit on Nail Disease, being held June 23 to 25 in Athens, Greece. The poster will include results of Viamet’s successful Phase 2b RENOVATE study for VT-1161, the Company’s novel inhibitor of fungal CYP51, in the treatment of moderate-to-severe distal-lateral subungual onychomycosis.